MiniMed Group, Inc.
MMED Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$18.34
KIRA · Stoqly’s AI analyst, in plain words
- MiniMed Group, Inc. had $3.1B of revenue in fiscal 2026, up 14.3% on the year before.
- Its operating margin was −6.1%, down 0.7 pts: of every 100 in sales, about −6 is left after running the business.
- MiniMed Group, Inc. lost $333M in fiscal 2026.
- Free cash flow was −$420M in fiscal 2026, −13.5% of revenue.
Market cap
$5.2B
P/E
—
Revenue
$3.1B
Net income
−$333M
Free cash flow
−$420M
Operating margin
−6.1%
MiniMed Group, Inc. in 30 seconds · fiscal 2026
Are sales growing?
+14.3%
Yes. Sales grew 14.3% last year.
Does it make a profit?
−10.7%
No. It lost money last year.
Does profit turn into cash?
−13.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MiniMed Group, Inc. does
No business description yet.
- Fiscal year ends
- April 24, 2026
- Latest annual report
- 10-K · Jun 29, 2026
- Legal name
- MiniMed Group, Inc.
- CIK
- 0002062583
MiniMed Group, Inc. · MMED
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $2.5B | $2.7B | $3.1B |
| Revenue growth | — | 10.0% | 14.3% |
| Gross margin | 58.2% | 56.3% | 54.2% |
| Operating margin | −2.8% | −5.4% | −6.1% |
| Net income | −$112M | −$213M | −$333M |
| Net margin | −4.5% | −7.8% | −10.7% |
| Diluted EPS | −$0.44 | −$0.84 | −$1.30 |
| Cash | |||
| Cash from operations | $41.0M | $140M | −$197M |
| Capital expenditure | $148M | $193M | $223M |
| Free cash flow | −$107M | −$53.0M | −$420M |
| FCF margin | −4.3% | −2.0% | −13.5% |
| Share count change | — | 0.0% | 1.5% |
| Debt and strength | |||
| Cash and short-term investments | $54.0M | $11.0M | $298M |
| Shareholders' equity | $3.4B | $3.3B | $3.6B |
| Current ratio | — | 1.3x | 1.9x |
| Returns and quality | |||
| Return on equity | −3.2% | −6.3% | −9.6% |
| Return on tangible equity | −3.2% | −22.6% | −26.7% |
| Piotroski F-score | — | — | 3 |
| Altman Z'' | — | 4.1 | 4.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MiniMed Group, Inc. · MMED
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $18.34 a share, the company is worth $5.2B.
Source: SEC EDGAR XBRL filings (CIK 0002062583). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.